These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28159621)

  • 41. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases.
    Goedert M; Spillantini MG; Serpell LC; Berriman J; Smith MJ; Jakes R; Crowther RA
    Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):213-27. PubMed ID: 11260802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
    Ciechanover A; Kwon YT
    Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions.
    Popescu A; Lippa CF; Lee VM; Trojanowski JQ
    Arch Neurol; 2004 Dec; 61(12):1915-9. PubMed ID: 15596612
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of physical exercise on β-amyloid, α-synuclein and tau accumulation: an in vitro model of oxidative stress in human red blood cells.
    Iofrida C; Daniele S; Pietrobono D; Fusi J; Galetta F; Trincavelli ML; Bonuccelli U; Franzoni F; Martini C
    Arch Ital Biol; 2017 Jul; 155(1-2):33-42. PubMed ID: 28715596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders.
    Kumar P; Pradhan K; Karunya R; Ambasta RK; Querfurth HW
    J Neurochem; 2012 Feb; 120(3):350-70. PubMed ID: 22098618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tau imaging in neurodegenerative diseases.
    Dani M; Brooks DJ; Edison P
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1139-50. PubMed ID: 26572762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuropathological spectrum of synucleinopathies.
    Jellinger KA
    Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach.
    Xu MM; Zhou MT; Li SW; Zhen XC; Yang S
    J Neurosci Res; 2021 May; 99(5):1308-1324. PubMed ID: 33634546
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases.
    Chin-Chan M; Navarro-Yepes J; Quintanilla-Vega B
    Front Cell Neurosci; 2015; 9():124. PubMed ID: 25914621
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic Review on Saliva Biomarkers in Patients Diagnosed with Morbus Alzheimer and Morbus Parkinson.
    Wolgin M; Zobernig M; Dvornyk V; Braun RJ; Kielbassa AM
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting Protein Aggregates with Natural Products: An Optional Strategy for Neurodegenerative Diseases.
    Xiang L; Wang Y; Liu S; Liu B; Jin X; Cao X
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Misfolded Protein Linked Strategies Toward Biomarker Development for Neurodegenerative Diseases.
    Kumar S; Karthikeyan N; Mishra S; Padmanabhan P; Radda G; Gulyás B
    Mol Neurobiol; 2019 Apr; 56(4):2559-2578. PubMed ID: 30043261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent High-Resolution Structures of Amyloids Involved in Neurodegenerative Diseases.
    Diaz-Espinoza R
    Front Aging Neurosci; 2021; 13():782617. PubMed ID: 34867305
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular pathology of neurodegenerative diseases: principles and practice.
    Kovacs GG
    J Clin Pathol; 2019 Nov; 72(11):725-735. PubMed ID: 31395625
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Unbiased Search of Biomarkers in Neurodegenerative Diseases.
    Ferrara P
    Curr Pharm Biotechnol; 2016; 17(5):471-9. PubMed ID: 26956112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute sleep deprivation in mice generates protein pathology consistent with neurodegenerative diseases.
    Rowe RK; Schulz P; He P; Mannino GS; Opp MR; Sierks MR
    Front Neurosci; 2024; 18():1436966. PubMed ID: 39114483
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lysophospholipids: A Potential Drug Candidates for Neurodegenerative Disorders.
    Karaki T; Haniu H; Matsuda Y; Tsukahara T
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551882
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advances in microfluidic chips targeting toxic aggregation proteins for neurodegenerative diseases.
    Li L; Lei T; Xing C; Du H
    Int J Biol Macromol; 2024 Jan; 256(Pt 2):128308. PubMed ID: 37992921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tunneling nanotubes: A novel pharmacological target for neurodegenerative diseases?
    Wang XT; Sun H; Chen NH; Yuan YH
    Pharmacol Res; 2021 Aug; 170():105541. PubMed ID: 33711434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.